Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

Martek Revenue Boosted By International Formula Sales

This article was originally published in The Tan Sheet

  • News

Executive Summary

International sales growth in the infant formula market drove a nearly 26% increase in Martek BioSciences' second-quarter revenues to $70.2 mil., the company reported June 7

You may also be interested in...



Martek DHA Gets Consumer-Friendly For Upcoming Functional Food Launches

A DHA-enriched Kellogg product may be the first functional food to launch with Martek's new life'sDHA brand name and logo on its label, according to a Sept. 6 analysts call

Martek DHA Gets Consumer-Friendly For Upcoming Functional Food Launches

A DHA-enriched Kellogg product may be the first functional food to launch with Martek's new life'sDHA brand name and logo on its label, according to a Sept. 6 analysts call

Martek DHA Gets Consumer-Friendly For Upcoming Functional Food Launches

A DHA-enriched Kellogg product may be the first functional food to launch with Martek's new life'sDHA brand name and logo on its label, according to a Sept. 6 analysts call

Table

View full table

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

US FDA’s Marks Willing To Accept Gene Therapies Occasionally Not Confirming Benefit

FDA Is ‘Getting More Aggressive’ In Going After Drug Efficacy Claims Outside Label

BIO’s New CEO Is Biotech Industry Veteran With Compelling Family Story, Ready To Take On The IRA

Patient-Focused Listening Sessions For Medicare-Negotiated Drugs: Key Takeaways From Round One

See All
UsernamePublicRestriction

Register

PS099451

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By